Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Deferred Revenue (2021 - 2023)

Historic Current Deferred Revenue for InMed Pharmaceuticals (INM) over the last 3 years, with Q4 2023 value amounting to $28656.0.

  • InMed Pharmaceuticals' Current Deferred Revenue rose 7720.61% to $28656.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $28656.0, marking a year-over-year increase of 7720.61%. This contributed to the annual value of $16171.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Current Deferred Revenue of $28656.0 as of Q4 2023, which was up 7720.61% from $16171.0 recorded in Q2 2023.
  • In the past 5 years, InMed Pharmaceuticals' Current Deferred Revenue ranged from a high of $28656.0 in Q4 2023 and a low of $8390.0 during Q4 2021
  • In the last 3 years, InMed Pharmaceuticals' Current Deferred Revenue had a median value of $16171.0 in 2022 and averaged $15737.3.
  • Per our database at Business Quant, InMed Pharmaceuticals' Current Deferred Revenue skyrocketed by 9274.14% in 2022 and then skyrocketed by 7720.61% in 2023.
  • Quarter analysis of 3 years shows InMed Pharmaceuticals' Current Deferred Revenue stood at $8390.0 in 2021, then skyrocketed by 92.74% to $16171.0 in 2022, then soared by 77.21% to $28656.0 in 2023.
  • Its last three reported values are $28656.0 in Q4 2023, $16171.0 for Q2 2023, and $16171.0 during Q1 2023.